Church of PeptidesSearch
Human trial evidence · Approved product with defined indications

Liraglutide

One molecule. Different questions. Six reading-room stops.

Patient One explores weight management, cardiovascular outcomes, kidney endpoints and the safety record. Fictional scenes accompany selected human studies and a separate regulatory checkpoint.

Journey published November 10, 2026 · Evidence reviewed 2026-11-10

Start at the beginning →Where we are today
  1. 01A scale is not a crystal ballHuman randomized trial · Published July 2, 2015
  2. 02The heart has its own questionHuman outcome trial · Published June 13, 2016
  3. 03Keep the other columnHuman LEADER safety · Published June 13, 2016
  4. 04The missing chairsHuman randomized follow-up · Published February 23, 2017
  5. 05Open the compositeHuman secondary analysis · Published August 31, 2017
  6. 06Read the actual labelRegulatory checkpoint · FDA label revised February 2026
Today’s checkpoint

November 10, 2026: a new historical journey, not a newly announced trial. Selected published studies and the retrieved February 2026 Saxenda label are reviewed; this is not a complete development dossier.

Open the medicine’s evidence profile · Other journeys

Documented milestones, not every unpublished experiment. The story is fictional; each chapter identifies the real study population and source.